For Our Patients
Clinical Trials and Research
Enrolling in
a Study
Thank you for your interest in enrolling in one of our studies.
New patients interested in participating in a clinical trial and in enrolling to possibly receive the newest, most advanced treatment for their vitreoretinal conditions, with the care and attention from our professional clinical trial staff.
Currently Enrolling Studies
New patients interested in enrolling a study, please click on the Enroll in this Study to send us an email. Include your name, the reason of your interest in this study and the office location you receive treatment. You will receive a reply from us within 48 - 72 hours.
The following studies are currently available for enrollment.
For Central Florida Patients
Genentech for Diabetic Macular Edema in underrepresented patients
A PHASE IIIB/IV, Multicenter, Open-label, Single-arm study to investigate Faricimab (RO6867461) Treatment response in treatment-naïve, Underpresented patients with Diabetic Macular Edema.
New Day is for Diabetic Macula EDEMA
A Randomized, Masked, Controlled Study of and Intravitreal ILUVIEN implant as baseline therapy in patients with Early Diabetic Macular Edema.
REGENXBIO for Wet AMD
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.
SHANGHAI HENLIUS for Wet AMD
A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in Subjects with wet Age-related Macular Degeneration (wAMD).
Closed for Enrollment
Oculis DX219 DIABETIC MACULAR EDEMA
A Phase 2/3 Pivotal, Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema.
Condor IS FOR PROLIFERATIVE DIABETIC RETINOPATHY
A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy.
Photon DIABETIC MACULAR EDEMA
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA
Notal Vision, Inc WET MACULAR DEGENERATION
The Evaluation of the Agreement and Precision of the Notal Vision Home OCT in the Automatic Fluid Quantification in Patients with NV-AMD
Hornbill is for Diabetic Retinopathy with Diabetic Macula Ischemia
A study to test the different doses of BI 764524 in patients who have had laser treatment for a type of diabetic eye disease called Diabetic Retinopathy with Diabetic Macula Ischemia
Kodiak KS301P106 (Glow) for NONPROLIFERATIVE DIABETIC RETINOPATHY
A Prospective, Randomized, Double-masked, Sham-controlled, Multicenter, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
Pulsar WET MACULAR DEGENERATION
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Kodiak Beacon KS301P103 MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multicenter, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal
KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment
Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)
Kodiak P104 (Gleam) for Diabetic Macular Edema
Randomized, Double masked Phase 3 study to evaluate the efficacy and safety of intravitreal KSI-301 compared with intravitreal Aflibercept in participants with visual impairment secondary to TREATMENT-NAÏVE Diabetic Macular Edema.
Kodiak Ks301P107 (Daylight) is for WET MACULAR DEGENERATION
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multicenter, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
For North Florida Patients
ADVM-022-11 – LUNA Neovascular (Wet) Age-Related Macular Degeneration
A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]
OcuTerra Therapeutics, Inc.- DREAM (NPDR/PDR)
OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
F. Hoffmann-La Roche- Diabetic Macular Edema
A Phase II, Multicenter, Randomized, Double Masked, Active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with Diabetic Macular Edema.
SHANGHAI HENLIUS FOR WET AMD
A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in Subjects with wet Age-related Macular Degeneration (wAMD).
ONL Therapeutics, Inc. (Retinal Detachment)
Protocol: ONL1204-RRD-002
A Phase 2, Randomized, Sham-Controlled, Single-Masked, Dose-Ranging, Multi-Center Study to Assess the Safety and Efficacy of Intravitreal ONL1204 in Subjects with Macula-off Rhegmatogenous Detachment.
DRCR-Protocol AF- Non-Proliferative Diabetic Retinopathy
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening.
DRCR-Protocol AJ- Macula Hole
Vitreous Proteomics in Eyes with a Macular Hole.
DRCR- Protocol AM- Epiretinal Membranes
Randomized Trial Comparing Immediate versus Deferred Surgery for Symptomatic Epiretinal Membranes.
Closed for Enrollment
Novartis Protocol RTH258D2301-PDR (CONDOR)
Proliferative Diabetic Retinopathy (PDR)
Central Florida and North Florida Patients
A 96-week, two arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy.
The purpose of this study is to evaluate the efficacy and safety of brolucizumab compared to PRP in subjects with PDR.
Regeneron Protocol 20968 (PULSAR)
Wet Macular Degeneration
Central Florida and North Florida Patients
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration.
Annexon Study
Geographic Atrophy Secondary to Age-Related Macular Degeneration
Central Florida and North Florida Patients
A phase 2, randomized, double masked, 4-armed, Sham controlled study of the efficacy, safety, and tolerability of ANX007 administered by intravitreal injections in patients with Geographic Atrophy secondary to age-related macular degeneration.
Gyroscope Study
Geographic Atrophy Secondary to Age-Related Macular Degeneration
Central Florida and North Florida Patients
To evaluate subjects with for Geographic Atrophy Secondary to Age-Related Macular Degeneration by sequencing selected genes associated with AMD. Subjects who meet eligibility criteria will have the option to participate in ongoing or future Gyroscope Therapeutic sponsored studies.
For more information about clinical trials or if you should have any questions, please feel free to contact us.
